Text Size

Pharmacotherapy for Schizophrenic Drug Users - 6

This study has been completed.
Sponsor:
Collaborator:
VA Connecticut Healthcare System
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000281
First received: September 20, 1999
Last updated: August 16, 2005
Last verified: December 2002
History of Changes
  Purpose

The purpose of this study is to evaluate maintenance neuroleptics for Schizophrenic patients who are cocaine abusers.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
 Behavioral: Amantadine
 Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy for Schizophrenic Drug Users

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Drug use
  • Retention
  • Psychological symptoms
  • Schizophrenic symptoms

Estimated Enrollment: 0
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000281

Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
VA Connecticut Healthcare System
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00000281     History of Changes
Other Study ID Numbers: NIDA-09250-6, P50-09250-6
Study First Received: September 20, 1999
Last Updated: August 16, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Amantadine
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antiviral Agents
 Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on May 21, 2013